PMID- 38037076
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Nov 30
TI  - Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal 
      carcinoma patients after failure of platinum-containing regimens: a systematic 
      review and meta-analysis.
PG  - 1172
LID - 10.1186/s12885-023-11318-y [doi]
LID - 1172
AB  - OBJECTIVE: There is a lack of standard salvage treatment options for recurrent or 
      metastatic nasopharyngeal carcinoma (RM-NPC) that has failed platinum-containing 
      regimens. Breakthroughs in immunotherapy have opened up new options for these 
      patients. However, the efficacy and safety of immunotherapy have not been 
      clarified. This study aimed to summarize and assess the efficacy and safety of 
      PD-1 inhibitors in patients with RM-NPC who failed platinum-containing 
      chemotherapy. METHODS: Up to August 25, 2022, clinical trials of PD-1 inhibitors 
      in RM-NPC patients who failed platinum-containing regimens were searched in the 
      PubMed, Embase, Cochrane, and Web of Science databases. Retrieval subject terms 
      included "nasopharyngeal carcinoma", "metastatic", "recurrence", "PD-1", and 
      "PD-L1". The clinical trials eligible for inclusion were systematically reviewed 
      and meta-analyzed. RESULTS: A total of 9 studies including 842 patients with 
      RM-NPC were included in this meta-analysis. The results showed that PD-1 
      inhibitors had promising efficacy in patients with RM-NPC who failed 
      platinum-containing regimens: objective response rate (ORR) was 24% (95% 
      confidence interval [CI] 21-26%), disease control rate (DCR) was 52% (95% CI 
      45-58%), 1-year progression-free survival (PFS) rate was 25% (95% CI 18-32%), and 
      1-year overall survival (OS) rate was 53% (95% CI 37-68%). In terms of 
      treatment-related adverse events (AEs), the incidence of grade >/= 3 
      treatment-related AEs was 19% (95% CI 13-24%). In addition, we found that PD-1 
      inhibitors were more effective in patients with PD-L1 positive than in patients 
      with PD-L1 negative nasopharyngeal carcinoma who had failed platinum-containing 
      regimens (ORR 31% (95%CI 26-35%) vs. 21% (95% CI 17-25%)). CONCLUSION: PD-1 
      inhibitors may provide a survival benefit for patients with RM-NPC who have 
      failed platinum-containing regimens and have the advantage of a good safety 
      profile, making them a promising treatment option.
CI  - (c) 2023. The Author(s).
FAU - Luo, Jian
AU  - Luo J
AD  - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical 
      University, Guangdong Pharmaceutical University, Guangzhou, 510062, China.
FAU - Xiao, Wanying
AU  - Xiao W
AD  - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical 
      University, Guangdong Pharmaceutical University, Guangzhou, 510062, China.
FAU - Hua, Fengyang
AU  - Hua F
AD  - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical 
      University, Guangdong Pharmaceutical University, Guangzhou, 510062, China.
FAU - Cao, Yanqing
AU  - Cao Y
AD  - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical 
      University, Guangdong Pharmaceutical University, Guangzhou, 510062, China.
FAU - Wang, Dongxia
AU  - Wang D
AD  - Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan 
      People's Hospital), Dongguan, 523058, China. dongxiadg@163.com.
FAU - Wang, Xicheng
AU  - Wang X
AD  - Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical 
      University, Guangdong Pharmaceutical University, Guangzhou, 510062, China. 
      13902400598@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231130
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 49DFR088MY (Platinum)
RN  - 0 (B7-H1 Antigen)
SB  - IM
MH  - Humans
MH  - Nasopharyngeal Carcinoma/drug therapy
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - Platinum/therapeutic use
MH  - B7-H1 Antigen
MH  - Neoplasm Recurrence, Local/drug therapy/pathology
MH  - *Nasopharyngeal Neoplasms/drug therapy
PMC - PMC10688056
OTO - NOTNLM
OT  - Efficacy
OT  - PD-1
OT  - Platinum-containing regimens
OT  - Recurrent or metastatic nasopharyngeal carcinoma
OT  - Safety
COIS- The authors declare no competing interests.
EDAT- 2023/12/01 06:44
MHDA- 2023/12/04 12:42
PMCR- 2023/11/30
CRDT- 2023/12/01 00:07
PHST- 2023/02/02 00:00 [received]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/12/01 06:44 [pubmed]
PHST- 2023/12/01 00:07 [entrez]
PHST- 2023/11/30 00:00 [pmc-release]
AID - 10.1186/s12885-023-11318-y [pii]
AID - 11318 [pii]
AID - 10.1186/s12885-023-11318-y [doi]
PST - epublish
SO  - BMC Cancer. 2023 Nov 30;23(1):1172. doi: 10.1186/s12885-023-11318-y.